US equities
|
SPCX
$167.19
▲+5.18%
NVDA
$236.90
▲+1.26%
MU
$1,064.94
▼-0.93%
TSLA
$375.73
▲+1.39%
MSFT
$526.70
▲+1.77%
INTC
$116.66
▼-2.24%
SNDK
$1,720.88
▲+0.05%
META
$744.15
▲+2.21%
SPCX
$167.19
▲+5.18%
NVDA
$236.90
▲+1.26%
MU
$1,064.94
▼-0.93%
TSLA
$375.73
▲+1.39%
MSFT
$526.70
▲+1.77%
INTC
$116.66
▼-2.24%
SNDK
$1,720.88
▲+0.05%
META
$744.15
▲+2.21%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Roivant Sciences Ltd. - Common Shares
(NQ:
ROIV
)
35.42
-0.30 (-0.83%)
Delayed Quote
Updated: 10:31 AM EDT, Oct 5, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Roivant Sciences Ltd. - Common Shares
< Previous
1
2
3
4
5
6
7
8
9
10
11
Next >
Roivant Sciences Targets LISRAYA Launch, Key Pipeline Readouts in Next 12 Months
↗
September 28, 2026
Roivant Sciences (NASDAQ:ROIV) CEO Matthew Gline outlined the company’s priorities for the next 12 months, including the launch of LISRAYA, upcoming clinical data for brepocitinib and Immunovant’s...
Via
MarketBeat
Topics
Government
Roivant Announces Topline Results from Proof-of-Concept Study of IMVT-1402 in Cutaneous Lupus Erythematosus
September 23, 2026
From
Roivant Sciences
Via
GlobeNewswire
There are notable gap-ups and gap-downs in today's session.
↗
September 08, 2026
Via
Chartmill
Roivant Announces Positive Results from PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) and Unveils Ongoing Phase 3 PHrontier Study
September 08, 2026
From
Roivant Sciences
Via
GlobeNewswire
ROIVANT SCIENCES LTD (NASDAQ:ROIV) Flashes Strong Breakout Setup with Near-Perfect Technical and Setup Quality Ratings
↗
May 14, 2026
Via
Chartmill
Pulmovant Announces Positive Results from PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) and Unveils Ongoing Phase 3 PHrontier Study
September 08, 2026
From
Pulmovant, Inc.
Via
GlobeNewswire
Pulmovant to Present Topline Results from the Phase 2 PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) at the ERS Congress 2026 on Tuesday, September 8, 2026
September 06, 2026
From
Pulmovant, Inc.
Via
GlobeNewswire
Roivant to Present Topline Results from the Phase 2 PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) at the ERS Congress 2026 on Tuesday, September 8, 2026, and Host Investor Call
September 06, 2026
From
Roivant Sciences
Via
GlobeNewswire
Roivant Sciences Wins FDA Approval for LISRAYA in Dermatomyositis, Launches Immediately
↗
August 28, 2026
Roivant Sciences (NASDAQ:ROIV) said the U.S. Food and Drug Administration has approved LISRAYA, its once-daily oral therapy for adults with dermatomyositis, and that the drug has already entered...
Via
MarketBeat
Topics
Government
Roivant Announces FDA Approval of LISRAYA™ (brepocitinib) for Adults with Dermatomyositis; Now Available in the U.S.
August 27, 2026
From
Roivant Sciences
Via
GlobeNewswire
Priovant Announces FDA Approval of LISRAYA™ (brepocitinib) for Adults with Dermatomyositis; Now Available in the U.S.
August 27, 2026
From
Roivant Sciences
Via
GlobeNewswire
JAMA Dermatology Publishes Skin-Specific Outcomes from Phase 3 VALOR Trial Of Brepocitinib in Dermatomyositis
August 26, 2026
From
Roivant Sciences
Via
GlobeNewswire
Roivant Sciences Q1 Earnings Call Highlights
↗
August 07, 2026
Roivant Sciences (NASDAQ:ROIV) said it expects a busy second half of 2026, with a potential launch of brepocitinib in dermatomyositis, several clinical readouts and additional regulatory discussions...
Via
MarketBeat
Topics
Earnings
Government
Roivant Reports Financial Results for the First Quarter Ended June 30, 2026, and Provides Business Update
August 06, 2026
From
Roivant Sciences
Via
GlobeNewswire
Priovant Announces First Patients Enrolled in Phase 3 Study (BEACON+) of Brepocitinib in Cutaneous Sarcoidosis (CS)
August 06, 2026
From
Roivant Sciences
Via
GlobeNewswire
Roivant to Report Financial Results for the First Quarter Ended June 30, 2026, and Provide Business Update on Thursday, August 6, 2026
July 23, 2026
From
Roivant Sciences
Via
GlobeNewswire
Could Roivant Sciences Be a Multibagger Stock Over the Next 5 Years?
↗
July 07, 2026
Wall Street expects sales to soar as several commercial launches approach.
Via
The Motley Fool
Roivant (ROIV) Q4 2025 Earnings Transcript
↗
May 20, 2026
Roivant (ROIV) Q4 2025 Earnings Transcript
Via
The Motley Fool
Roivant Sciences Q4 Earnings Call Highlights
↗
May 20, 2026
Roivant Sciences (NASDAQ:ROIV) executives used the company’s fourth-quarter earnings call to highlight new open-label data for IMVT-1402 in difficult-to-treat rheumatoid arthritis, upcoming pulmonary...
Via
MarketBeat
Topics
Earnings
Government
Stay updated with the stocks that are on the move in today's pre-market session.
↗
May 20, 2026
Via
Chartmill
Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 and Provides Business Update
May 20, 2026
From
Roivant Sciences
Via
GlobeNewswire
Hedge Fund Wagers $36 Million on Biotech Denali After First FDA Approval
↗
May 18, 2026
This biotech develops therapies for neurodegenerative diseases, advancing a broad pipeline through strategic pharmaceutical partnerships.
Via
The Motley Fool
Topics
Regulatory Compliance
Hedge Fund Drops $40 Million on Gene-Editing Biotech Beam. Is It a Buy?
↗
May 18, 2026
Beam Therapeutics develops precision genetic medicines using base editing technology to target serious inherited diseases.
Via
The Motley Fool
Hedge Fund Drops $37 Million on Rare Disease Biotech Crinetics. Is It a Buy?
↗
May 18, 2026
Crinetics Pharmaceuticals develops oral therapies for rare endocrine diseases.
Via
The Motley Fool
Topics
ETFs
Regulatory Compliance
Patient Square Makes a Big Bet on Nektar Pharmaceuticals (NKTR) Purchasing 210,000 Shares
↗
May 16, 2026
This biotech firm develops immunotherapies for cancer and autoimmune diseases, with several candidates advancing through clinical trials.
Via
The Motley Fool
Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 and Provide Business Update on Wednesday, May 20, 2026
May 11, 2026
From
Roivant Sciences
Via
GlobeNewswire
Roivant and Immunovant Solidify Market Leadership as Brepocitinib and FcRn Programs Hit Critical Clinical Milestones
April 02, 2026
The biotechnology sector witnessed a seismic shift this week as Roivant Sciences (Nasdaq: ROIV) and its subsidiary Immunovant (Nasdaq: IMVT) reported a series of clinical and regulatory updates that...
Via
MarketMinute
Topics
Intellectual Property
Roivant Announces Expansion of Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP) and Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED)
April 02, 2026
From
Roivant Sciences
Via
GlobeNewswire
Priovant Expands Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP)
April 02, 2026
From
Roivant Sciences
Via
GlobeNewswire
New England Journal of Medicine Publishes Positive Phase 3 VALOR Trial Results of Brepocitinib in Dermatomyositis
March 28, 2026
From
Roivant Sciences
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
9
10
11
Next >
